Assessment of clot degradation under the action of histotripsy and a thrombolytic drug

2020 ◽  
Vol 148 (4) ◽  
pp. 2801-2802
Author(s):  
Samuel A. Hendley ◽  
Jonathan Paul ◽  
Kenneth B. Bader
Keyword(s):  
Thrombolytic Drug

scholarly journals Efficacy of thrombolytics in patients with acute coronary syndrome

2021 ◽  
Vol 10 (Supplement_1) ◽  
Author(s):  
A Vasin ◽  
O Mironova ◽  
V Fomin
Keyword(s):  
Acute Coronary Syndrome ◽  
Chest Pain ◽  
Thrombolytic Therapy ◽  
Prehospital Care ◽  
Optimal Choice ◽  
Hospital Treatment ◽  
Complication Rates ◽  
Coronary Syndrome ◽  
Thrombolytic Drug ◽  
Systemic Thrombolytic Therapy

Abstract Funding Acknowledgements Type of funding sources: None. Background/Introduction: The optimal choice of the thrombolytic drug for emergency revascularization in patients with acute coronary syndrome (ACS) still remains to be defined. Percutaneous coronary intervention is a more safe and effective method of reperfusion compared with thrombolytic therapy, that’s why the last is relatively not common nowadays. But in the COVID-19 era in a number of cases some patients with ACS can’t be quickly hospitalized due to different reasons like the absence of the nearest available cardiovascular center, or lack of an ambulance. A long period of chest pain forces the doctors to use systemic thrombolytic therapy. Purpose This study investigates the efficacy and safety of Alteplase, Prourokinase, Tenecteplase, and Streptokinase in patients with acute coronary syndrome. Methods A retrospective, open, non-randomized cohort study was conducted. We have analysed 600 patients with ACS, who underwent systemic thrombolytic therapy at the prehospital and in-hospital stages from 2009 to 2011. Patients were divided into several groups according to the thrombolytic agent administered: Alteplase (254 patients), Prourokinase (309 patients), Tenecteplase (6 patients), Streptokinase (31 patients). Treatments were to be given as soon as possible. The ECG reperfusion criterion was a decrease in the ST segment by 50% or more from the initial elevation. Results  Among 600 patients (mean age, 61 years (SD = 20); 119 women [19.7%]), 440 had successful reperfusion. The median time from chest pain onset to the start of treatment was 3 hours (P < 0.001). The percentages of successful thrombolysis for each agent were similar: Alteplase 74,4% Prourokinase 71,2%, Tenecteplase 83%, Streptokinase 74,2%. No statistical differences were observed in thrombolytic results among these groups (OR: 0.60, 95% CI: 0,2868 to 1,217; P = 0.17). At the same time, the hospital treatment with prourokinase was more effective than prehospital care with prourokinase: 110 successful reperfusions in 138 patients (79.7%) and 110 successful reperfusions in 171 patients (64.3%), respectively. Regardless of the onset of the attack (OR: 0.45, 95% CI: 0,2004 to 0,9913; P = 0.05). The effectiveness of the other thrombolytics cannot be compared between prehospital care and hospital treatment due to the rare use at the hospital stage in our cases. In the study, there was also no statistical difference in complication rates among the treatment groups. Among all patients, there were 9 fatal outcomes (1.5%): Alteplase 3,15% Prourokinase 1,9%, Streptokinase 3,22%. Conclusion(s): In patients with ACS, all thrombolytic drugs showed similar effectiveness. There is no difference in the safety and efficacy among the agents in our study, but there is a difference in cost and route of administration. However, upcoming prospective trials with long follow-up periods might be expected to determine the most appropriate systemic thrombolytic drug.

Study on the therapeutic and nursing effect of thrombus targeted thrombolysis mediated by recombinant plasminogen activator modified nanoparticles on stroke patients

2021 ◽  
Vol 11 (7) ◽  
pp. 1024-1030
Author(s):  
Li Zhang ◽  
Miao Xu ◽  
Min Zhu ◽  
Andong Liu ◽  
Fenghua Zhao
Keyword(s):  
Drug Therapy ◽  
Plasminogen Activator ◽  
Survival Rates ◽  
Clinical Applications ◽  
The Self ◽  
Therapeutic Effects ◽  
Stroke Patients ◽  
Traditional Treatment ◽  
Thrombolytic Drug ◽  
Tissue Plasminogen

Tissue plasminogen activator (rt-PA) is a thrombolytic drug used for the treatment of stroke. However, it has a short half-life and a high risk of complications of cerebral hemorrhage, which complicates its use in clinical applications. In this study, polyethylene glycol and polycaprolactone were used as nano-carriers in the development of new nano-drug-recombinant plasminogen activator modified nanoparticles (PEG-PCL@rt-PA) loaded with rt-PA. Following treatment, the patients received with either conventional nursing or continuous nursing. Compared with traditional treatment and nursing, the nanoparticles had stronger thrombolytic and therapeutic effects, significantly improved the self-care recovery rate of patients, and reduced the occurrence of complications. This new mode of PEG-PCL@rt-PA drug therapy combined with continuous nursing is expected to improve the recovery and survival rates of stroke patients.

Is there any need for a TAFI(a) inhibitor as thrombolytic drug?

2012 ◽  
Vol 130 (4) ◽  
pp. 574-575
Author(s):  
Ellen Vercauteren ◽  
Ann Gils
Keyword(s):  
Thrombolytic Drug

Bioresponsive Polyphenol-Based Nanoparticles as Thrombolytic Drug Carriers

2022 ◽  
Author(s):  
Haitao Yu ◽  
Jason S. Palazzolo ◽  
Jiajing Zhou ◽  
Yingjie Hu ◽  
Be’eri Niego ◽  
...  
Keyword(s):  
Drug Carriers ◽  
Thrombolytic Drug

Thrombolysis in Central Splanchnic Thrombosis

1997 ◽  
Vol 12 (5) ◽  
pp. 269-275
Author(s):  
Hendrik E. Demey ◽  
Guy Lambrecht ◽  
Greta Moorkens ◽  
Peter Michielsen ◽  
Jef Van Den Ende ◽  
...  
Keyword(s):  
Abdominal Pain ◽  
Venous Thrombosis ◽  
Lupus Anticoagulant ◽  
Superior Mesenteric Vein ◽  
Therapeutic Option ◽  
Literature Survey ◽  
High Dose ◽  
Mesenteric Vein ◽  
Vein Thrombosis ◽  
Thrombolytic Drug

We present 4 patients treated with streptokinase for different forms of abdominal venous thrombosis. Two patients suffered from central splanchnic venous thrombosis (superior mesenteric vein and bilateral iliac veins in Patient A, portal and superior mesenteric veins in Patient B). Both patients' presenting complaint was abdominal pain. In both, a temporary infection-associated circulating lupus anticoagulant presumably caused this condition. Two other patients presented with isolated portal vein thrombosis without lupus anticoagulant. Thrombolysis with high dose streptokinase (9 MU over 6 hours) successfully reopened the veins involved in all 4 patients. A literature survey showed that thrombolysis is a therapeutic option for mesenteric vein thrombosis, but there was no consensus on which thrombolytic drug should be given or on method of administration.

T-cell recognition of discrete regions of the thrombolytic drug streptokinase

2000 ◽  
Vol 99 (3) ◽  
pp. 239 ◽  
Author(s):  
Wendy J. LAWLEY ◽  
Sue FLETCHER ◽  
Iain B. SQUIRE ◽  
Kent L. WOODS ◽  
Colin R.A. HEWITT
Keyword(s):  
T Cell ◽  
Cell Recognition ◽  
T Cell Recognition ◽  
Thrombolytic Drug

Ultrasound-Induced Blood Clot Dissolution without a Thrombolytic Drug Is More Effective with Lower Frequencies

2005 ◽  
Vol 20 (1) ◽  
pp. 18-22 ◽  
Author(s):  
Max Nedelmann ◽  
Christian Brandt ◽  
Felicitas Schneider ◽  
B. Martin Eicke ◽  
Oliver Kempski ◽  
...  
Keyword(s):  
Blood Clot ◽  
Thrombolytic Drug ◽  
Lower Frequencies

scholarly journals Tenecteplase for the treatment of acute ischemic stroke: A review of completed and ongoing randomized controlled trials

2018 ◽  
Vol 13 (9) ◽  
pp. 885-892 ◽  
Author(s):  
Shelagh B Coutts ◽  
Eivind Berge ◽  
Bruce CV Campbell ◽  
Keith W Muir ◽  
Mark W Parsons
Keyword(s):  
Ischemic Stroke ◽  
Acute Ischemic Stroke ◽  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Genetically Engineered ◽  
Bolus Administration ◽  
Thrombolytic Drug ◽  
Tissue Plasminogen ◽  
Activator Inhibitor ◽  
Stroke Trial

Alteplase has been the mainstay of thrombolytic treatment since the National Institutes of Neurological Disorders and Stroke trial was published in 1995. Over recent years, several trials have investigated alternative thrombolytic agents. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, has a longer half-life, allowing single intravenous bolus administration without infusion, is more fibrin specific, produces less systemic depletion of circulating fibrinogen, and is more resistant to plasminogen activator inhibitor compared to alteplase. Tenecteplase is established as the first-line intravenous thrombolytic drug for myocardial infarction, where it has been shown to achieve comparable reperfusion with reduced risk of systemic bleeding in comparison to alteplase. We review the literature on tenecteplase for the treatment of acute ischemic stroke, with a focus on the major completed and ongoing trials. Overall, tenecteplase shows promise for treatment of acute ischemic stroke, both in populations currently eligible for alteplase and also in groups not currently treated with thrombolysis.

Sign in / Sign up

Export Citation Format

Share Document